Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
Astellas and Vir Biotechnology collaborate to advance a novel PSMA-targeting treatment for prostate cancer, promising new hope for patients worldwide.